Pacira BioSciences urges shareholders to vote for board nominees
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- McKesson reports cybersecurity incident affecting its information systems
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
Pacira BioSciences Mails Letter to Stockholders
May 5, 2026 4:20 PM EDTDetails Success of Paciras 5x30 Strategy and Solid First Quarter 2026 ResultsÂ
Reiterates Boards Unanimous Recommendation that Stockholders Vote FOR the Election of Paciras Highly Qualified Nominees on the BLUE Proxy Card Today
BRISBANE, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX) (the Company or Pacira), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has mailed a letter to stockholders in connection with the Companys 2026... More
